Erle Refsum

Erle Refsum

Auto-generated profile, based on publicly available information

Erle Refsum

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
JYJingru Yu
Jingru Yu
ERErle Refsum
Erle Refsum
LHLise M. Helsingen
Lise M. Helsingen
TFTrine Folseraas
Trine Folseraas
APAlexander Ploner
Alexander Ploner
WYWeimin Ye
Weimin Ye
Background: There is continued uncertainty regarding the risks of hepato‐pancreato‐biliary cancers in patients with inflammatory bowel disease (IBD) with or without concomitant primary sclerosing cholangitis (PSC).Objective: To give updated estimates on risk of hepato‐pancreato‐biliary cancers in patients with IBD, including pancreatic cancer, hepatocellular carcinoma, gall bladder cancer, and intra – and extrahepatic cholangiocarcinoma.Methods: In a population‐based cohort study, we included all patients diagnosed with IBD in Norway and Sweden from 1987 to 2016. The cohort comprised of 141,960 patients, identified through hospital databases and the National Patient Register. Participants were followed through linkage to national cancer, cause of death, and population registries. We calculated absolute risk and standardized incidence ratios (SIRs) of hepato‐pancreato‐biliary cancers by PSC and other clinical characteristics.Results: Of the 141,960 IBD patients, 3.2% were diagnosed with PSC. During a median follow‐up of 10.0 years, we identified 443 biliary tract cancers (SIR 5.2, 95% confidence interval [CI] 4.8–5.7), 161 hepatocellular carcinomas (SIR 2.4, 95% CI 2.0–2.7) and 282 pancreatic cancers (SIR 1.3, 95% CI 1.2–1.5). The relative risks were considerably higher in PSC‐IBD patients, with SIR of 140 (95% CI 123–159) for biliary tract, 38.6 (95% CI 29.2–50.0) for hepatocellular, and 9.0 (95% CI 6.3–12.6) for pancreatic cancer. The SIRs were still slightly increased in non‐PSC‐IBD patients, compared to the general population. For biliary tract cancer, the cumulative probability at 25 years was 15.6% in PSC‐IBD patients, and 0.4% in non‐PSC‐IBD patients.Conclusions: The dramatically increased risks of hepato‐pancreato‐biliary cancers in PSC‐IBD patients support periodic surveillance for these malignancies. While much lower, the excess relative risks in non‐PSC‐IBD patients were not trivial compared to non‐IBD related risk factors.

30 October 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HJHenriette C. Jodal
Henriette C. Jodal
DKDagmar Klotz
Dagmar Klotz
MHMagnhild Herfindal
Magnhild Herfindal
IBIshita Barua
Ishita Barua
PTPetter Tag
Petter Tag
MLMagnus Løberg
Magnus Løberg
Summary: Background: Women and men with colorectal adenomas are at increased risk of colorectal cancer and colonoscopic surveillance is recommended. However, the long‐term cancer risk remains unknown.Aims: To investigate colorectal cancer incidence and mortality after adenoma removal in women and menMethods: We identified all individuals who had adenomas removed in Norway from 1993 to 2007, with follow‐up through 2018. We calculated standardized incidence ratios (SIR) and incidence‐based mortality ratios (SMR) with 95% confidence intervals (CI) for colorectal cancer in women and men using the female and male population for comparison. We defined high‐risk adenomas as ≥2 adenomas, villous component, or high‐grade dysplasia.Results: The cohort comprised 40 293 individuals. During median follow‐up of 13.0 years, 1079 women (5.5%) and 866 men (4.2%) developed colorectal cancer; 328 women (1.7%) and 275 men (1.3%) died of colorectal cancer. Colorectal cancer incidence was more increased in women (SIR 1.64, 95% CI 1.54‐1.74) than in men (SIR 1.12, 95% CI 1.05‐1.19). Colorectal cancer mortality was increased in women (SMR 1.13, 95% CI 1.02‐1.26) and reduced in men (SMR 0.79, 95% CI 0.71‐0.89). Women with high‐risk adenomas had an increased risk of colorectal cancer death (SMR 1.37, 95% CI 1.19‐1.57); women with low‐risk adenomas (SMR 0.90, 95% CI 0.76‐1.07) and men with high‐risk adenomas had a similar risk (SMR 0.89, 95% CI 0.76‐1.04), while men with low‐risk adenomas had reduced risk (SMR 0.70, 95% CI 0.59‐0.84).Conclusions: After adenoma removal, women had an increased risk of colorectal cancer death, while men had reduced risk, compared to the general female and male populations. Sex‐specific surveillance recommendations after adenoma removal should be considered.

1 August 2017 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
JDJesper Dahl
Jesper Dahl
ERErle Refsum
Erle Refsum
MAMaria Therese Ahlen
Maria Therese Ahlen
TETorstein Egeland
Torstein Egeland
TJTore Jensen
Tore Jensen
HTHeidi Tiller
Heidi Tiller

4 May 2023 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
JYJingru Yu
Jingru Yu
ERErle Refsum
Erle Refsum
PWPaulina Wieszczy
Paulina Wieszczy
LHLise M Helsingen
Lise M Helsingen
VPVera Perrin
Vera Perrin
MKMette Kalager
Mette Kalager
Objective To estimate the risk of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) in patients with inflammatory bowel disease (IBD). Design We undertook a two-country population cohort study with all patients diagnosed with IBD in Norway and Sweden from 1987 and 1993 through 2015 and 2016, respectively, and analysed the risk of NHL and HL. In Sweden, we also analysed prescriptions of thiopurines and anti-tumour necrosis factor (TNF)-α therapy from 2005. We calculated standardised incidence ratios (SIRs) with 95% CIs using the general populations as reference. Results Among 131 492 patients with IBD with a medium follow-up of 9.6 years, we identified 369 cases of NHL and 44 cases of HL. The SIR of NHL was 1.3 (95% CI 1.1 to 1.5) in ulcerative colitis and 1.4 (95% CI 1.2 to 1.7) in Crohn’s disease. We found no compelling heterogeneity in analyses stratified by patient characteristics. We found a similar pattern and magnitude of excess risks for HL. At 10 years, cumulative incidence was 0.26% (95% CI 0.23% to 0.30%) and 0.06% (95% CI 0.04% to 0.08%) for NHL and HL, respectively. Higher excess risks were found among patients with NHL with concomitant primary sclerosing cholangitis (SIR 3.4; 95% CI 2.1 to 5.2) and in those prescribed thiopurines alone (SIR 2.8; 95% CI 1.4 to 5.7) or with anti-TNF-α agents (SIR 5.7; 95% CI 2.7 to 11.9). Conclusion Patients with IBD have a statistically significant increased risk of malignant lymphomas compared with the general population, but the absolute risk remains low.

1 July 2016 in Journal of Immunological Methods
Verified
Journal Article
Closed access
AMAnette Mörtberg
Anette Mörtberg
SMStephan Meinke
Stephan Meinke
PBPetra Berg
Petra Berg
MKMette Kjær Killie
Mette Kjær Killie
JKJens Kjeldsen-Kragh
Jens Kjeldsen-Kragh
AWAgneta Wikman
Agneta Wikman

8 November 2017 in Transfusion
Verified
Journal Article
Closed access
PDF file
ERErle Refsum
Erle Refsum
SHStellan Håkansson
Stellan Håkansson
AMAnette Mörtberg
Anette Mörtberg
AWAgneta Wikman
Agneta Wikman
MWMagnus Westgren
Magnus Westgren